Core Viewpoint - Health 160 has been included in the short-selling designated securities list by the Hong Kong Stock Exchange, which is a routine adjustment based on market liquidity and market capitalization, and does not reflect the company's fundamental performance or operational status [1][2] Group 1: Market Reaction and Stock Performance - Following its inclusion in the short-selling list, Health 160's stock price experienced short-term fluctuations, primarily driven by market sentiment and investor misunderstanding of market rules, rather than a true reflection of the company's intrinsic value [2] - Since the beginning of 2026, Health 160's stock has shown a steady upward trend, with a peak increase of 62.55%, closing at HKD 90.80 on February 10, 2026, with a total market capitalization of HKD 30.55 billion [2] Group 2: Company Growth and Future Outlook - Health 160 is accelerating its layout in the AI + healthcare sector, with multiple institutions raising their target prices, reflecting strong confidence in the company's growth prospects [2] - On February 5, Huasheng Securities raised Health 160's target price to HKD 150.15, indicating a potential upside of approximately 69.57%, and forecasts the company will achieve profitability by 2026 with a projected net profit of HKD 96 million [2] - Revenue growth rates are expected to increase significantly from 11.65% to 57.04% from 2025 to 2027, indicating an accelerating growth trend [2] Group 3: Competitive Position and Technological Advancements - As a leading player in China's digital healthcare sector, Health 160 has established a comprehensive digital healthcare ecosystem, differentiating itself from competitors like OpenEvidence by covering the entire patient journey with its AI health management system [3] - The company's AI applications have generated substantial economic value, with its OCR technology achieving an accuracy rate of 89%, significantly higher than the industry average [4] - Health 160's platform connects over 44,800 healthcare institutions, including 3,441 tertiary hospitals, and has registered 56.9 million personal users, creating a robust ecosystem that supports the application of AI technology [4] Group 4: Strategic Focus and Investor Communication - Health 160's inclusion in the short-selling list will not alter its development strategy or operational pace, as the company remains focused on deepening its digital healthcare ecosystem and enhancing the application of AI technology in the healthcare sector [4] - The company emphasizes the importance of investors maintaining a rational perspective on short-term market fluctuations and focusing on the company's fundamentals and long-term value [4]
健康160（02656.HK）股价短期波动系市场规则正常运行 AI+医疗生态布局持续深化